Veco Labs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 08-07-2024
- Paid Up Capital ₹ 1.50 Cr
as on 08-07-2024
- Company Age 30 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.86 Cr
as on 08-07-2024
- Satisfied Charges ₹ 6.08 M
as on 08-07-2024
- Revenue 10.71%
(FY 2022)
- Profit -0.73%
(FY 2022)
- Ebitda 18.42%
(FY 2022)
- Net Worth 8.19%
(FY 2022)
- Total Assets 13.95%
(FY 2022)
About Veco Labs
The Corporate was formerly known as Sree Rama Pharma Chemicals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹5.86 Cr. The company has closed loans amounting to ₹6.08 M, as per Ministry of Corporate Affairs (MCA) records.
Abbaraju Babu and Repala Rao serve as directors at the Company.
- CIN/LLPIN
U24239TG1994PTC017212
- Company No.
017212
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Mar 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Veco Labs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Repala Rao  | Managing Director | 11-Feb-2002 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abbaraju Babu | Whole-Time Director | 22-Sep-2007 | Current |
Financial Performance of Veco Labs.
Veco Labs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 10.71% increase. The company also saw a slight decrease in profitability, with a 0.73% decrease in profit. The company's net worth moved up by a moderate rise of 8.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Veco Labs?
In 2021, Veco Labs had a promoter holding of 38.08% and a public holding of 61.92%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Sep 2007 | ₹5.71 Cr | Open |
Karnataka Bank Ltd Creation Date: 09 Nov 1988 | ₹1.50 M | Open |
Karnataka Bank Ltd. Creation Date: 25 Aug 2001 | ₹0.48 M | Satisfied |
How Many Employees Work at Veco Labs?
Unlock and access historical data on people associated with Veco Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Veco Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Veco Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
